Literature DB >> 15650062

CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response.

Gregor S D Reid1, Kevin She, Luke Terrett, Michael R Food, Jacqueline D Trudeau, Kirk R Schultz.   

Abstract

Immunostimulatory DNA containing unmethylated cytosine-phosphate-guanosine (CpG) induces the development of T helper 1 (Th1) immune responses. The response of B cells to CpG stimulation involves increased proliferation, cytokine production, and costimulatory molecule expression. Similar effects have been observed following CpG stimulation of a variety of malignant B cells. Pediatric precursor B acute lymphoblastic leukemia (B-ALL) cells express low levels of costimulatory molecules and are generally poor stimulators of T-cell responses. In this study, we evaluated the impact of CpG stimulation on precursor B-ALL cell lines and pediatric patient-derived samples. The ability to respond to CpG oligodeoxynucleotides was determined by the level of Toll-like receptor 9 (TLR9) expression. In contrast to both nonleukemic B-cell precursors and mature B cells, the response of precursor B-ALL cells was characterized by increased CD40 expression but only small changes in CD86 levels and no induction of CD80 expression. CpG stimulation of ALL blasts produced increased levels of interleukin-6 (IL-6), IL-8, and IL-10 but no detectable IL-12p70 and led to a skewing of allogeneic T cells, with enhanced interferon gamma (IFN-gamma) production and reduced secretion of IL-5. These results demonstrate the functional relevance of CpG stimulation of precursor B-ALL cells and provide a rational basis for study of these agents for use in treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650062     DOI: 10.1182/blood-2004-06-2468

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  Toll-like receptors: lessons to learn from normal and malignant human B cells.

Authors:  David Chiron; Isabelle Bekeredjian-Ding; Catherine Pellat-Deceunynck; Régis Bataille; Gaëtan Jego
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

2.  Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees.

Authors:  Bindu Varghese; Adam Widman; James Do; Behnaz Taidi; Debra K Czerwinski; John Timmerman; Shoshana Levy; Ronald Levy
Journal:  Blood       Date:  2009-09-17       Impact factor: 22.113

3.  Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses.

Authors:  Alix E Seif; David M Barrett; Michael Milone; Valerie I Brown; Stephan A Grupp; Gregor S D Reid
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

4.  Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting.

Authors:  Christian M Capitini; Laurence J N Cooper; R Maarten Egeler; Rupert Handgretinger; Franco Locatelli; Paul M Sondel; Crystal L Mackall
Journal:  J Pediatr Hematol Oncol       Date:  2009-04       Impact factor: 1.289

Review 5.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 6.  The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

Authors:  Kenneth R Cooke; Leo Luznik; Stefanie Sarantopoulos; Frances T Hakim; Madan Jagasia; Daniel H Fowler; Marcel R M van den Brink; John A Hansen; Robertson Parkman; David B Miklos; Paul J Martin; Sophie Paczesny; Georgia Vogelsang; Steven Pavletic; Jerome Ritz; Kirk R Schultz; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-03       Impact factor: 5.742

7.  Murine pre-B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor.

Authors:  Haiying Qin; Kazusa Ishii; Sang Nguyen; Paul P Su; Chad R Burk; Bong-Hyun Kim; Brynn B Duncan; Samikasha Tarun; Nirali N Shah; M Eric Kohler; Terry J Fry
Journal:  Blood       Date:  2018-09-12       Impact factor: 22.113

8.  Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival.

Authors:  Sara Maia; Marc Pelletier; Jixin Ding; Yen-Ming Hsu; Stephen E Sallan; Sambasiva P Rao; Lee M Nadler; Angelo A Cardoso
Journal:  PLoS One       Date:  2011-06-08       Impact factor: 3.240

Review 9.  Toll-like receptors in the pathogenesis of human B cell malignancies.

Authors:  Johana M Isaza-Correa; Zheng Liang; Anke van den Berg; Arjan Diepstra; Lydia Visser
Journal:  J Hematol Oncol       Date:  2014-08-12       Impact factor: 17.388

10.  Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists.

Authors:  Sumin Jo; Abbas Fotovati; Jesus Duque-Afonso; Michael L Cleary; Peter van den Elzen; Alix E Seif; Gregor S D Reid
Journal:  Cancers (Basel)       Date:  2020-01-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.